drugset / Trial / NCT01119235

A Study To Observe The Performance Of A Tablet Form Of PF-04531083 As Evidenced By The Concentration Of PF-04531083 In The Blood With Time Following Oral Administration To Healthy Volunteers.

NCT01119235

Phase 1 Completed 24 enrolled Pfizer
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A new tablet form of PF-04531083 has been manufactured. Previously the compound was administered as a solution/suspension to healthy volunteers. This study will investigate the pharmacokinetics of PF-044531083 in tablet form and compare with the pharmacokinetics obtained, with the same dosing regimen, with the solution/suspension.

Timeline

Start
2010-05
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator PF-04531083 Small molecule 200 mg Oral

Indications